<DOC>
	<DOCNO>NCT03038308</DOCNO>
	<brief_summary>The purpose study evaluate use non-ergoline dopamine agonist ropinirole treatment hyperprolactinemia patient idiopathic hyperprolactinemia prolactinomas .</brief_summary>
	<brief_title>Treatment Hyperprolactinemia With Non-ergoline Dopamine Agonist Ropinirole</brief_title>
	<detailed_description>Treatment prolactin secrete pituitary tumor traditional ergot dopamine agonist drug limited medication side effect , pharmacologic resistance , concern regard potential risk cardiac valve disease . The overall goal project therefore evaluate , first time , efficacy tolerability selective D2/D3 receptor non-ergot dopamine agonist ropinirole treatment prolactinomas . This proposal establish pharmacologic profile medication use treat hyperprolactinemia patient prolactinomas determine impact long-term ropinirole administration critical clinical parameter include serum prolactin level , gonadal function , tumor regression , order establish ropinirole 's utility new , clinically efficacious , safer tolerable therapeutic option treatment prolactinomas may prove particularly useful patient underlie cardiac valve disease resistance intolerance ergot dopamine agonist .</detailed_description>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<mesh_term>Prolactinoma</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>Ages 1870 year Prolactin level ( PRL ) ≥2 time upper limit normal Pituitary adenoma MRI ≤ 1.5cm great diameter ≥ 5mm optic chiasm Normal renal liver function Agrees barrier contraception premenopausal Use medication know interfere PRL secretion PRL Ropinirole ( ROP ) metabolism Use another dopamine agonist 4 week prior Pituitary stalk compression MRI History visual field abnormality previous radiation Untreated hypothyroidism Consumption &gt; 2 alcoholic drink per day Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ropinirole</keyword>
	<keyword>hyperprolactinemia</keyword>
	<keyword>prolactin</keyword>
</DOC>